Trends in Immunotherapy

Article

Estimation of gene expression level of CDH1 as a predisposing factor for metastasis in localized and locally advanced and metastatic breast cancer Iraqi patients

Downloads

https://doi.org/10.24294/ti.v7.i2.2935
Talib Abdallah, M., Aziz, I., & Zuhair Alsammarraie, A. (2023). Estimation of gene expression level of CDH1 as a predisposing factor for metastasis in localized and locally advanced and metastatic breast cancer Iraqi patients. Trends in Immunotherapy, 7(2). https://doi.org/10.24294/ti.v7.i2.2935
Volume 7 Issue 2 (2023)

Copyright

The authors shall retain the copyright of their work but allow the Publisher to publish, copy, distribute, and convey the work.

License

Trends in Immunotherapy (TI)  publishes accepted manuscripts under Creative Commons Attribution 4.0 International (CC BY 4.0). Authors who submit their papers for publication by TI agree to have the CC BY 4.0 license applied to their work, and that anyone is allowed to reuse the article or part of it free of charge for any purpose, including commercial use. As long as the author and original source are properly cited, anyone may copy, redistribute, reuse, and transform the content.

Authors

  • Mays Talib Abdallah
    Institute of Genetic Engineering and Biotechnology, University of Baghdad, Jadriyah, Baghdad 10070, Iraq
  • Ismail Aziz Institute of Genetic Engineering and Biotechnology, University of Baghdad, Jadriyah, Baghdad 10070, Iraq
  • Ahmed Zuhair Alsammarraie Oncology Teaching Hospital Baghdad, Baghdad 10047, Iraq

Breast cancer (BC) is a prevalent malignancy among women, ranking as the second most commonly diagnosed cancer globally. Notably, a substantial proportion of breast cancer-related fatalities, up to 90 percent, are attributed to the development of distant organ metastases. While Cadherin1 (CDH1) has conventionally been considered a tumor-suppressor gene in cancer research, recent investigations have unequivocally revealed that both CDH1 and its encoded E-cadherin exhibit oncogenic characteristics. The primary focus of this case-control study is to ascertain the involvement of the CDH1 gene in a specific subset of Iraqi female patients. A total of ninety patients sought diagnosis and treatment at the Oncology Teaching Hospital in Medical City and the Oncology Unit at Al-Yarmouk Teaching Hospital in Baghdad. In addition, we included 30 apparently healthy individuals as blood control subjects and another 30 women with benign breast tumors as tissue control subjects for the study. In the initial phase of the study, we conducted a serological analysis using enzyme-linked immunosorbent assay (ELISA) to detect the concentration of E-cadherin in serum samples from two groups of BC patients. The group with locally advanced and metastatic BC exhibited a significantly higher E-cadherin concentration (963.4 ± 89.8 pg/mL) compared to the group with localized BC. In the second part of the research, qRT-PCR was performed to analyze the expression of the CDH1 gene across all sample types. CDH1 was shown to have the greatest fold expression (2.550 ± 0.164) in cases with locally progressed and metastatic BC. Compared to the seemingly healthy control group, the fold expression for localized BC was 1.456 ± 0.055, and for malignant tissue it was 1.886 ± 0.08621. In conclusion, this study provides compelling evidence supporting CDH1 as an oncogene in BC. The significance of CDH1 in BC tumorigenesis underscores its potential for the development of novel detection biomarkers and targeted therapeutic approaches for BC treatment. Notably, CDH1 exhibited elevated expression levels in BC tissues and demonstrated an association with an unfavorable distant metastasis-free survival outcome.

Keywords:

CDH1 breast cancer oncogenic characteristics metastasis gene expression E-cadherin

References

  1. Alabedi H. Assessing setup errors and shifting margins for planning target volume in head, neck, and breast cancer. Journal of Medicine and Life 2023; 16(3): 394–398. doi: 10.25122/jml-2022-0241
  2. Abbas RAR, Aziz IH. A study comparing the oncogenic microRNA-21-5P and the CA15-3 characteristics as an effective tumor marker in breast cancer patients from Iraq. Revis Bionatura 2022; 7(4): 1–7. doi: 10.21931/rb/2022.07.04.10
  3. Raheem AR, Abdul-Rasheed OF, Al-Naqqash MA. The diagnostic power of circulating micro ribonucleic acid 34a in combination with cancer antigen 15-3 as a potential biomarker of breast cancer. Saudi Medical Journal 2019; 40(12): 1218–1226. doi: 10.15537/smj.2019.12.24712
  4. Saeed Hadi H, Abdulzahra Abbas S. Oxidative Stress biomarkers levels in blood sample of Iraqi breast cancer patients. Research Journal of Pharmacy and Technology 2023; 16(5): 2364–2368. doi: 10.52711/0974-360x.2023.00389
  5. Leong SP, Naxerova K, Keller L, et al. Molecular mechanisms of cancer metastasis via the lymphatic versus the blood vessels. Clinical and Experimental Metastasis 2022; 39(1): 159–179. doi: 10.1007/s10585-021-10120-z
  6. Fahad Ullah M. Breast cancer: Current perspectives on the disease status. In: Ahmad A (editor). Breast Cancer Metastasis and Drug Resistance, 2nd ed. Springer; 2019. pp. 57–58.
  7. Shenoy S. CDH1 (E-cadherin) mutation and gastric cancer: Genetics, molecular mechanisms and guidelines for management. Cancer Management and Research 2019; 11: 10477–10486. doi: 10.2147/cmar.s208818
  8. Ismael MK, Qaddoori YB, Shaban MN, AL-Rubaii BAL. The immunohistochemical staining of vimentin and E-cadherin in bladder cancer patients infected with hepatitis C virus. Journal of Pure and Applied Microbiology 2023; 17(2): 1009–1016. doi: 10.22207/jpam.17.2.30
  9. Alshami ML, Aswad F, Abdullah B. Desmogleins 1, 3, and E-cadherin immunohistochemical expression within mucocutaneous pemphigus vulgaris. Pan African Medical Journal 2022; 42. doi: 10.22207/jpam.17.2.30
  10. Jaafer SF, Aziz IH. Identification of E-cadherin methylation in Iraqi breast cancer patients. Iraqi Journal of Biotechnology 2017; 16(1): 101–105.
  11. Daulagala AC, Bridges MC, Kourtidis A. E-cadherin beyond structure: A signaling hub in colon homeostasis and disease. International Journal of Molecular Sciences 2019; 20(1): 2756. doi: 10.3390/ijms20112756
  12. Xie D, Chen Y, Wan X, et al. The potential role of CDH1 as an oncogene combined with related miRNAs and their diagnostic value in breast cancer. Frontiers in Endocrinology 2022; 13. doi: 10.3389/fendo.2022.916469
  13. Gharbi S, Mohammadi Z, Dezaki MS, et al. Characterization of the first microRNA in human CDH1 that affects cell cycle and apoptosis and indicates breast cancer progression. Journal of Cellular Biology 2022; 123(3): 657–672. doi: 10.1002/jcb.30211
  14. Alabassi HM. Assessment of ZYXIN and E-cadherin tumour marker in Iraqi patients with glioma lesion of the brain. Biochemical and Cellular Archives 2019; 19(2): 4379–4383. doi: 10.35124/bca.2019.19.2.4379
  15. Nieto MA, Huang RY, Jackson RA, Thiery JP. EMT: 2016. Cell 2016; 166(1): 21–45. doi: 10.1016/j.cell.2016.06.028
  16. Ye T, Li J, Sun Z, et al. Cdh1 functions as an oncogene by inducing self-renewal of lung cancer stem-like cells via oncogenic pathways. International Journal of Biological Sciences 2020; 16(3): 447–459. doi: 10.7150/ijbs.38672
  17. Bae KM, Su Z, Frye C, Mcclellan S, et al. Expression of pluripotent stem cell reprogramming factors by prostate tumor initiating cells. Journal of Urology 2010; 183(5): 2045–2053. doi: 10.1016/j.juro.2009.12.092
  18. Ku SC, Liu HL, Su CY, et al. Comprehensive analysis of prognostic significance of cadherin (CDH) gene family in breast cancer. Aging 2022; 14(20): 8498–8567. doi: 10.18632/aging.204357
  19. Tsaur I, Thurn K, Juengel E, et al. sE-cadherin serves as a diagnostic and predictive parameter in prostate cancer patients. Journal of Experimental &, Clinical Cancer Research 2015; 34(1). doi: 10.1186/s13046-015-0161-6
  20. Padmanaban V, Krol I, Suhail Y, et al. E-cadherin is required for metastasis in multiple models of breast cancer. Nature 2019; 573(7774): 439–444. doi: 10.1038/s41586-019-1526-3
  21. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCT method. Methods 2001; 25(4): 402–408. doi: 10.1006/meth.2001.1262
  22. Latorre E, Harries Lorna W. Splicing regulatory factors, ageing and age-related disease. Ageing Research Reviews 2017; 36: 165–170. doi: 10.1016/j.arr.2017.04.004
  23. Dogra S, Dunstan DW, Sugiyama T, et al. Active aging and public health: Evidence, implications, and opportunities. Annual Review of Public Health 2022; 43(1): 439–459. doi: 10.1146/annurev-publhealth-052620-091107
  24. Sicairos, B., Alam, S., & Du, Y. A comprehensive analysis of different types of databases reveals that CDH1 mRNA and E‑cadherin protein are not downregulated in most carcinoma tissues and carcinoma cell lines. BMC Cancer 2023; 23(1), 441. https://doi.org/10.1186/s12885-023-10916-0
  25. Labrèche F, Goldberg MS, Hashim D, Weiderpass E. Breast cancer. Occupational Cancers 2020; 417–438. doi: 10.1007/978-3-030-30766-0_24
  26. Sahan KA, Aziz IH, Dawood SN, Al Qazzaz H. The role of resistin gene polymorphism in Iraqi breast cancer patients. Biomedicine 2022; 42(6): 1296–1300. doi: 10.51248/.v42i6.2393
  27. Alsammarraie AZ, Mubarak AA, Alnuaimi AS, et al. Association of oral contraceptives use with breast cancer and hormone receptor status in Iraqi women. Macedonian Journal of Medical Sciences 2020; 8(B): 1244–1250. doi: 10.3889/oamjms.2020.5030
  28. Abdou, Y., Gupta, M., Asaoka, M., Attwood, K., Mateusz, O., Gandhi, S., & Takabe, K. Left-sided breast cancer is associated with aggressive biology and worse outcomes than right-sided breast cancer. Scientific Reports 2022; 12, 13377. doi: 10.1038/s41598-022-16749-4
  29. Abdou Y, Gupta M, Asaoka M, et al. Left sided breast cancer is associated with aggressive biology and worse outcomes than right sided breast cancer. Scientific Reports 2022; 12(1). doi: 10.1038/s41598-022-16749-4
  30. Weltz C, Port E. Surgical risk reduction, breast cancer and childbearing. Current Breast Cancer Reports 2021; 13(3): 113–118. doi: 10.1007/s12609-021-00424-0
  31. Qiu R, Zhong Y, Hu M, et al. Breastfeeding and reduced risk of breast cancer: A systematic review and meta-analysis. Computational and Mathematical Methods in Medicine 2022; 2022: 1–9. doi: 10.1155/2022/8500910
  32. Cabrera L, Trapero I. Evaluation of the effectiveness of breastfeeding as a factor in the prevention of breast cancer. Endocrine, Metabolic &, Immune Disorders—Drug Targets 2022; 22(1): 15–25. doi: 10.2174/1871530321666210427083707
  33. Cobain EF, Milliron KJ, Merajver SD. Updates on breast cancer genetics: Clinical implications of detecting syndromes of inherited increased susceptibility to breast cancer. Seminars in Oncology 2016; 43(5): 528–535. doi: 10.1053/j.seminoncol.2016.10.001
  34. Shiyanbola OO, Arao RF, Miglioretti DL, et al. Emerging trends in family history of breast cancer and associated risk. Cancer Epidemiology, Biomarkers & Prevention 2017; 26(12): 1753–1760. doi: 10.1158/1055-9965.epi-17-0531
  35. Mboungou Malanda DM, Boumba ALM, Malonga GA. Breast cancer in women: Epidemiological, histological, immunohistochemical and molecular sub-types in the Republic of Congo. International Journal of Health Sciences and Research 2021; 11(5): 103–116. doi: 10.52403/ijhsr.20210515
  36. Gautam N, Verma H, Choudhary S, et al. Functional relationship of SNP (Ala490Thr) of an epigenetic gene EZH2 results in the progression and poor survival of ER+/tamoxifen treated breast cancer patients. Journal of Genetics 2021; 100(2). doi: 10.1007/s12041-021-01327-w
  37. Al Zobair AA, Jasim BI, Al Obeidy BF, et al. Prognostic impact of hormone and HER2 status on the prognosis of breast cancer in Mosul. Annals of Tropical Medicine and Public Health 2020; 23(7): 274–285. doi: 10.36295/asro.2020.2375
  38. Zhou X, Gao W, Hua H, et al. LncRNA-BLACAT1 facilitates proliferation, migration and aerobic glycolysis of pancreatic cancer cells by repressing CDKN1C via EZH2-induced H3K27me3. Frontiers in Oncology 2020; 10. doi: 10.3389/fonc.2020.539805
  39. Waks AG, Winer EP. Breast cancer treatment. JAMA 2019; 321(3): 316. doi: 10.1001/jama.2018.20751
  40. Al-Bedairy IH, AlFaisal AHM, Al-Gazali HR, Al M. Molecular subtypes by immunohistochemical for Iraqi women with breast cancer. Iraqi Journal of Biotechnology (IJB) 2020; 19(1): 18–27.
  41. Alshewered AF, Al-Nuaimi DS, Al-Naqqash MA, Alshewered AS. Time to progression of early versus advance breast cancer in Iraq. Prensa Médica Argentina 2020; 106(1): 1–5. doi: 10.47275/0032-745x-171
  42. Pandit P, Patil R, Palwe V, et al. Prevalence of molecular subtypes of breast cancer: A single institutional experience of 2062 patients. European Journal of Breast Health 2020; 16(1): 39–43. doi: 10.5152/ejbh.2019.4997
  43. Errahhali ME, Errahhali ME, Ouarzane M, et al. First report on molecular breast cancer subtypes and their clinico-pathological characteristics in Eastern Morocco: Series of 2260 cases. BMC Women’s Health 2017; 17(1): 1–11. doi: 10.1186/s12905-016-0361-z
  44. Abed SN, Mahdi HS, Sahib AS, et al. Serum levels of cancer antigen 15.3 and estrogen in a sample of Iraqi women with breast cancer treated with Anastrazole. International Journal of Pharmaceutical Research 2020; 12(1): 1604–1608. doi: 10.31838/ijpr/2020.sp1.246
  45. Hussain AMA, Lafta RK. Cancer trends in Iraq 2000–2016. Oman Medical Journal 2021; 36(1): e219–e219. doi: 10.5001/omj.2021.18
  46. Al-hamadawi HA, Al-Kashwan TA, Al-Janabi AA, et al. Interaction between altered P53 and PTEN inactivation has a biological predictive implication in the assessment of aggressive breast cancer. International Journal of Current Microbiology and Applied Sciences 2015; 4(5): 910–922.
  47. Celik, B., & Tuncer, S. B. Investigation of CDH1 germline mutations in Turkish patients with Kaposi’s sarcoma. Turkish Journal of Biochemistry 2022. https://doi.org/10.1515/tjb-2022-0032
  48. Bae KM, Parker NN, Dai Y, et al. E-cadherin plasticity in prostate cancer stem cell invasion. American Journal of Cancer Research 2011; 1(1): 71–84.
  49. Manuel Iglesias J, Beloqui I, Garcia-Garcia F, et al. Mammosphere formation in breast carcinoma cell lines depends upon expression of E-cadherin. PLoS ONE 2013; 8(10): e77281. doi: 10.1371/journal.pone.0077281
  50. Kourtidis A, Lu R, Pence LJ, et al. A central role for cadherin signaling in cancer. Experimental Cell Research 2017; 358(1): 78–85. doi: 10.1016/j.yexcr.2017.04.006
  51. Porto-Mascarenhas EC, Assad DX, Chardin H, et al. Salivary biomarkers in the diagnosis of breast cancer: A review. Critical Reviews in Oncology/Hematology 2017; 110: 62–73. doi: 10.1016/j.critrevonc.2016.12.009
  52. Ceresa D, Alessandrini F, Bosio L, et al. Cdh4 down-regulation impairs in vivo infiltration and malignancy in patients derived glioblastoma cells. International Journal of Molecular Sciences 2019; 20(16): 4028. doi: 10.3390/ijms20164028
  53. Venhuizen JH, Span P, van den Dries K, et al. P120 catenin isoforms differentially associate with breast cancer invasion and metastasis. Cancers 2019; 11(10): 1459. doi: 10.3390/cancers11101459
  54. Ribatti D, Tamma R, Annese T. Epithelial-mesenchymal transition in cancer: A historical overview. Translational Oncology 2020; 13(6): 100773. doi: 10.1016/j.tranon.2020.100773
  55. Liang Z, Sun XY, Xu LC, Fu RZ. Abnormal expression of serum soluble E-cadherin is correlated with clinicopathological features and prognosis of breast cancer. Medical Science Monitor 2014; 20: 2776–2782. doi: 10.12659/MSM.892049
  56. Burandt E, Lübbersmeyer F, Gorbokon N, et al. E-cadherin expression in human tumors: a tissue microarray study on 10,851 tumors. Biomarker Research 2021; 9(1). doi: 10.1186/s40364-021-00299-4
  57. Chang, I., & Chang, I. Increased soluble E‑cadherin of spheroid formation supplemented with fetal bovine serum in colorectal cancer cells. Oncology Letters 2023; 25, 207. doi:10.3892/ol.2023.13793
  58. Gogali A, Charalabopoulos K, Zampira I, et al. Soluble adhesion molecules E-cadherin, intercellular adhesion molecule-1, and e-selectin as lung cancer biomarkers. Chest 2010; 138(5): 1173–1179. doi: 10.1378/chest.10-0157
  59. Repetto O, De Paoli P, De Re V, et al. Levels of soluble E-cadherin in breast, gastric, and colorectal cancers. BioMed Research International 2014; 2014: 1–7. doi: 10.1155/2014/408047